Advancing ALK+ NSCLC Care: Optimizing Treatment, Sequencing, and Long-Term Outcomes
Ryan Haumschild, PharmD, MS, MBA, CPEL; Elizabeth Castronovo, NP; Martin Dietrich, MD, PhD; Mary Grizzard, MSN, FNP; and Christine M. Lovly, MD, PhD, FASCO, discuss how advances in ALK-positive non–small cell lung cancer (ALK+ NSCLC) treatment, including 5-year CROWN trial data for lorlatinib, recent ensartinib approval, comparative efficacy against brain metastases, toxicity management strategies, and sequencing approaches following progression are reshaping clinical decision-making to optimize long-term patient outcomes.
Episodes
May 5th 2025EP. 1: The Evolution of ALK+ NSCLC Care
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of emerging clinical data.
May 5th 2025EP. 2: Lorlatinib in Focus: Survival, Brain Metastases, and Beyond
Panelists discuss how the 5-year CROWN trial data for lorlatinib have shaped the treatment paradigm for ALK+ metastatic non-small cell lung cancer (NSCLC), particularly regarding long-term survival, durability of response, and management of brain metastases.
May 12th 2025EP. 3: Choosing Wisely: Insights from an MAIC and eXalt3
Panelists discuss how matching-adjusted indirect comparisons (MAIC) of ALK inhibitors and the FDA approval of ensartinib in December 2024 influence frontline treatment selection for ALK+ non–small cell lung cancer (NSCLC).
May 12th 2025EP. 4: Applying Trial Data to Real-World Practice in ALK+ NSCLC
Panelists discuss how clinical trial outcomes like CROWN and eXalt3 reflect real-world patient experiences and how these collective data have changed perspectives on frontline therapies for ALK+ non–small cell lung cancer (NSCLC).
May 19th 2025EP. 5: Key Differences Among ALK Inhibitors
Panelists discuss how currently available ALK inhibitors compare in terms of efficacy, durability of response, and central nervous system (CNS) penetration for metastatic non–small cell lung cancer treatment.
May 19th 2025EP. 6: Navigating ALK Inhibitor Toxicities
Panelists discuss how ALK inhibitors compare in terms of tolerability and best practices for managing associated toxicities.
May 26th 2025EP. 7: Lorlatinib’s Unique Challenges: Managing Cognitive and Metabolic AEs
Panelists discuss how lorlatinib’s unique adverse event (AE) profile, including cognitive effects, hypercholesterolemia, and peripheral neuropathy, impacts treatment selection and patient management.
May 26th 2025EP. 8: Long-Term Success: Educating and Supporting Patients on ALK Inhibitors
Panelists discuss how proactive patient education, lipid-lowering interventions, and monitoring tools can help patients stay on ALK inhibitor therapy to realize long-term benefits.
